Allergan plc (NYSE:AGN) registered a 0.83% increase, still its new closing price is 17.38% up from the company’s 1 year high of 301.98.It posted -2.12% losses in previous 5 sessions and is now the subject of 5 analysts who together assign a hold rating on stock. 0 of Wall Street analysts have an underperform rating; the 0 sells versus 8 buy or better ratings. The 22 stock analysts following this company have an average price target at $260.63, with individual PT in the $202.00-$400.00 range. The shares moved at $216.56, implying that brokerage firms see shares losing about -25.78% in twelve months time.
Allergan plc (AGN) SEC Form 4 News
The stock is getting much attention these days as insiders are offloading shares while they posted a 3.12% rise year to date. A Director at Allergan plc (AGN) offloaded shares in a transaction closed on Thursday December 08, 2016. Basgoz Nesli sold 500 shares in the company at $188.72 each and collected $94,000 in proceeds. Basgoz Nesli now owns 5,515 shares in the company after this transaction. A CEO and President in the company, SAUNDERS BRENT L, disclosed a transaction on Monday November 21, 2016 that ended up paying $992,001 from the purchase of 5,250 shares at $189.13 per share.
Allergan plc (NYSE:AGN) Upcoming Results on Tap
Allergan plc will next provide financial results for the March 2017 quarter. Stock analysts expect it to report per-share earnings of $3.94 in that period. Sales during the quarter are predicted to arrive at $3.58 billion.
Earnings surprise history: Last quarter, the company posted approximately $3.62 billion in revenue and EPS of $3.32. The mean forecast was for $3.68 billion and $3.56 a share, respectively. One quarter earlier, revenue for the stock was at $3.68 billion, with earnings at $3.35/share.
Allergan plc (AGN) Brokerage Update
Allergan plc (AGN) is in Mizuho’s research list so their analyst rating change is noteworthy. These shares were upgraded to Buy from Neutral by Mizuho, according to news reported on Friday August 19, 2016.Another important research note was issued by Piper Jaffray on Monday April 18, 2016.The firm downgraded AGN to Neutral from Overweight. Over the last six months and over the last three months, the shares of Allergan plc (AGN), have changed -10.75% and -3.32%, respectively.